S
Stanley J. Goldsmith
Researcher at Cornell University
Publications - 290
Citations - 13155
Stanley J. Goldsmith is an academic researcher from Cornell University. The author has contributed to research in topics: Prostate cancer & Radioimmunotherapy. The author has an hindex of 61, co-authored 290 publications receiving 12418 citations. Previous affiliations of Stanley J. Goldsmith include City University of New York & North Shore-LIJ Health System.
Papers
More filters
Journal ArticleDOI
NANETS treatment guidelines: well-differentiated neuroendocrine tumors of the stomach and pancreas.
Matthew H. Kulke,Lowell Anthony,David L. Bushnell,Wouter W. de Herder,Stanley J. Goldsmith,David S. Klimstra,Stephen J. Marx,Janice L. Pasieka,Rodney F. Pommier,James C. Yao,Robert T. Jensen +10 more
TL;DR: An overview of well-differentiated neuroendocrine tumors of the stomach and pancreas is provided and consensus guidelines for the treatment of patients with these malignancies are described.
Journal ArticleDOI
Phase I Trial of 177Lutetium-Labeled J591, a Monoclonal Antibody to Prostate-Specific Membrane Antigen, in Patients With Androgen-Independent Prostate Cancer
Neil H. Bander,Matthew I. Milowsky,David M. Nanus,Lale Kostakoglu,Shankar Vallabhajosula,Stanley J. Goldsmith +5 more
TL;DR: Acceptable toxicity, excellent targeting of known sites of PC metastases, and biologic activity in patients with androgen-independent PC warrant further investigation.
Journal ArticleDOI
The NANETS Consensus Guideline for the Diagnosis and Management of Neuroendocrine Tumors Well-Differentiated Neuroendocrine Tumors of the Jejunum, Ileum, Appendix, and Cecum
J. Philip Boudreaux,David S. Klimstra,Manal M. Hassan,Eugene A. Woltering,Robert T. Jensen,Stanley J. Goldsmith,Charles Nutting,David L. Bushnell,Martyn Caplin,James C. Yao +9 more
TL;DR: Well-differentiated neuroendocrine tumors (NETs) of the jejunum, ileum, and appendix are also collectively known as midgut carcinoids and have substantial risk of relapse after resection and need to be followed for at least 7 years.
Journal ArticleDOI
Phase II study of Lutetium-177-labeled anti-prostate-specific membrane antigen monoclonal antibody J591 for metastatic castration-resistant prostate cancer
Scott T. Tagawa,Matthew I. Milowsky,Michael J. Morris,Shankar Vallabhajosula,Paul J. Christos,Naveed Akhtar,Joseph R. Osborne,Stanley J. Goldsmith,Steve Larson,Neeta Pandit Taskar,Howard I. Scher,Neil H. Bander,David M. Nanus +12 more
TL;DR: A single dose of 177Lu-J591 was well tolerated with reversible myelosuppression and accurate tumor targeting and PSA responses were seen with evidence of dose response.
Journal Article
PET Predicts Prognosis After 1 Cycle of Chemotherapy in Aggressive Lymphoma and Hodgkin’s Disease
TL;DR: F-FDG PET after 1 cycle of chemotherapy is predictive of 18-mo outcome in patients with aggressive NHL and HD and may earlier identify patients who would benefit from more intensive treatment programs.